Comment from Biocom

Summary: Biocom, a trade association representing California's life science sector, supports the FDA's proposed Expedited Investigational New Drug (IND) pilot program to reduce time to first-in-human clinical trials. They offer specific recommendations to improve the program's design, including clarifying Qualified Research Institution (QRI) roles, establishing clear success metrics, and ensuring consistent regulatory oversight.